Dan Groman - 14 Nov 2023 Form 4 Insider Report for Enfusion, Inc.

Reporting relationship: Chief Technology Officer
Issuer ticker: N/A
Reported as of: 14 Nov 2023
Net transaction value: -$49,850
SEC form: 4
Accepted by SEC: 16 Nov 2023, 20:30:30 UTC
Prior SEC filing: 19 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/ Matthew Campobasso, as Attorney-in-Fact

Filing notes and source

Key filing fact

Dan Groman filed Form 4 for Enfusion, Inc. on 16 Nov 2023.

Key facts

This page summarizes Dan Groman's Form 4 filing for Enfusion, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Nov 2023, 20:30.

Change

Previous filing in this sequence was filed on 19 Oct 2023.
Current net transaction value: -$49,850.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENFN transaction

Class A Common Stock

Sale

Transaction value: $49,850
Shares: -5,000
Change %: -3.6%
Price: $9.97
Shares after: 133,828
Date: 14 Nov 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on June 15, 2023.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.83 to $10.19. Full information regarding the number of shares sold at each separate price will be furnished to the SEC staff upon request.